Objective: HIV-positive women have higher human papillomavirus (HPV) prevalence and cervical cancer incidence than HIV-negative women, partly because of HIV's modifying effect on HPV pathogenesis. We synthesized the literature on the impact of HIV on HPV natural history.
Introduction
Cervical cancer is the fourth most common cancer in women worldwide and the most common cancer among women in sub-Saharan Africa [1] . Sub-Saharan Africa has high dual burden of human papillomavirus (HPV) and HIV infection [2, 3] . HIV is associated with higher rates of HPV acquisition, decreased clearance of HPV and precancerous lesions, and increased risk of cervical cancer [4, 5] . Compared with HIV-negative women, cervical cancer mortality in HIV-positive women is 2 times higher [6, 7] . With increasing life expectancy of HIV-Further, although many studies have evaluated the relationship between HIV and HPV pathogenesis, the findings have not been synthesized. Although ART decreases the incidence of other AIDS-related cancers, its relationship with cervical cancer is unclear [16, 17, 14] . We conducted a systematic review and meta-analysis to synthesize the literature on HPV natural history in HIVpositive women. Specifically, we evaluate the risk of HPV incidence, persistence, and progression to cervical lesions and cancer among HIV-positive women compared with HIV-negative women. We additionally assess these relationships by CD4 þ cell counts, HIV viral load, and ART use.
Methods

Study objectives
We sought to assess the interactions between HIVand HPV on the incidence of HPV infection; persistence/clearance of HPV infection; progression from HPV infection to lowgrade squamous intraepithelial lesion (LSIL); progression from LSIL to high-grade squamous intraepithelial lesion (HSIL); regression from LSIL; regression from HSIL; and progression to invasive cervical cancer. HPV pathogenesis in HIV-positive women was compared with HIV-negative women. We assessed the modifying effect of CD4 þ cell count, HIV viral load, and ART on the interactions between HIV and HPV.
Inclusion/exclusion criteria
Eligible studies examined the acquisition, persistence, or clearance of HPV or the incidence, progression, and regression of cervical lesions by HIV status, CD4 þ cell count, HIV viral load, and ART using cohort or casecontrol study design. Studies assessing HPV incidence were included only if they adjusted for confounders identified in previous literature (e.g. age, number of sex partners, etc.) or identified in their data; however, we did not restrict on specific confounders (Appendix Table 3 , http://links.lww.com/QAD/B224). Studies grouping LSIL and HSIL together were only included if proportions of LSIL and HSIL were reported. If more than 85% of lesions detected were LSIL, we considered the estimates to approximate LSIL natural history.
Search strategy
Following PRISMA guidelines, we conducted a systematic search on PubMed, Embase, Global Health Database, reference list of eligible articles, and conference abstracts (Appendix Tables 1 and 2 , http://links.lww.com/QAD/ B224) [18] . Search terms included HIV, HPV, cervical lesion, and disease progression. We included only primary research articles, but did not restrict on language or publication date. Additional details about the search strategy are available in the Appendix, http://links.lww. com/QAD/B224.
Study quality assessment
We assessed the risk of bias (low, moderate, high) in studies using modified criteria for nonrandomized observational studies across five domains: study population, detection of outcome and exposure, bias related to study design, statistical analysis, and disclosure of conflict of interest [19, 20] . See Appendix Figures 1 and 2 , http:// links.lww.com/QAD/B224 for detailed study quality assessment.
Statistical analysis
Whenever possible, effects by HIV status, CD4 þ cell count, and ART use were pooled using fixed effect models with inverse variance weighting (SAS 9.4; SAS Institute Inc., Cary, North Carolina, USA). We combined estimates with the same measures of association [e.g. relative risk, odds ratio (OR), or hazard ratio]. We quantified heterogeneity with I 2 . When the number of studies in a meta-analysis is small, I
2 was sometimes a negative value and set to zero.
Results
The search was conducted on 19 May 2017 and yielded 1845 studies. We excluded 1726 studies after screening abstracts (Fig. 1) . Primary reasons for exclusions were ineligible study design and HPV infection site. We further excluded 81 studies after reading the full text. Overall, 38 studies were included (Table 1) . Most studies were prospective cohort (n ¼ 34); the remaining were retrospective cohort (n ¼ 2), nested case-control (n ¼ 1), and case-crossover (n ¼ 1). Most were conducted in North America (n ¼ 18) or Africa (n ¼ 13). The United States (n ¼ 15) and South Africa (n ¼ 7) were the most frequently represented countries. One study was conducted in Asia and six in Europe. Half of studies included HIV-negative women as the comparison group (n ¼ 23). Papanicolaou (Pap) smear was most commonly used to collect cervical specimens and polymerase chain reaction using L1 consensus primers was most common method for genotype detection.
The majority of studies had low risk of bias in the selection of study population (79%), ascertainment of exposure and outcome variables (76%), and statistical analysis (71%) (Appendix Figures 2 and 3 , http:// links.lww.com/QAD/B224). Only 32% had low risk of study design-specific bias, because of incomplete ascertainment of ART use or high loss to follow-up.
Human papillomavirus incidence
Twelve studies assessed HPV incidence [5, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] , seven included HIV-negative women as reference [5, 21, 22, 26, 28, 31] Fig. 2a ).
CD4
R cell count Four studies found that CD4 þ cell count modified HPV acquisition in HIV-positive women [5, 23, 28, 31] . Women with high CD4 þ cell count (>500 cells/ml) were at greater risk of infection compared with HIV-negative women, and risk dramatically increased with declining Minkoff et al.
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Case-crossover CD4 þ cell count (Fig. 2b) [5, 28, 31] . One study found the risk of HPV infection decreased by 18% with every 100-cell increase in CD4 þ (OR 0.82, 95% CI 0.70-0.96) [23] . Two studies found higher CD4 þ cell count did not significantly reduce HPV incidence (Appendix Table 3 , http://links.lww.com/QAD/B224) [25, 26] .
Antiretroviral therapy
Three of the four studies that ascertained ART use from medical records or self-reports found no association between ART and HPV incidence (Appendix Table 3 , http://links.lww.com/QAD/B224) [25, 28, 30] ; whereas one study found ART reduced HPV 16 and 18 incidence by 72% (RR 0.28, 95% CI 0.09-0.86) but not any HPV incidence (RR 0.79, 95% CI 0.28-2.23) [24] . One study comparing effective ART (defined as reducing HIV viral load by >90% or to undetectable), to no treatment found that effective ART decreased incidence of any HPV by 36% (OR 0.64, 95% CI 0.46-0.88) but the impact on high-risk HPV incidence was not statistically significant (OR 0.62, 95% CI 0.38-1.02) [27] .
HIV viral load
Two studies evaluated the role of HIV viral load on HPV acquisition [5, 26] . Compared with HIV-negative women, the risk of any HPV infection was 3.29 times (95% CI 2.18-4.95) higher among HIV-positive women with viral load more than 10 000 copies/ml and 2.31 times (95% CI 1.49-3.58) higher among those with viral load less than 10 000 copies/ml [26] . Further, HPV acquisition was higher with increasing viral load among women with CD4 þ cell count greater than 200 cells/ml (Fig. 2b) , although no pattern in HPVacquisition by viral load was observed in women with CD4 þ cell count less than 200 cells/ml [5] .
Human papillomavirus reactivation
One study found that new HPV infections were detected in women who reported no sexual activity in the last 18 months, indicating potential reactivation of latent infections. The rate of potential reactivations was 1.4-4.4 times higher among HIV-positive compared with HIVnegative women [5] .
Human papillomavirus persistence and clearance Two studies evaluated clearance among women with incident HPV infection [5, 32] . HIV-positive women were 28% less likely than HIV-negative women to clear infection with any HPV (hazard ratio pooled 0.72, 95% CI 0.62-0.84; Fig. 3a) . Eleven studies evaluated clearance of incident and prevalent HPV infections together [22, [25] [26] [27] 29, [32] [33] [34] [35] [36] [37] (Fig. 3b) [22, 26, 32, 33] . However, pooled effects based on two Zeier et al.
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Women with low CD4 þ cell count (<200 cells/ml) had much lower likelihood of HPV clearance compared with Incidence of HPV infection by HPV type. Banura et al. [21] was not included in calculating the overall effect because it reported odds ratio; other studies reported relative risk. (b) Relative incidence of any HPV infection, by CD4 þ cell count. The effect estimates from Strickler et al. [5] were stratified HIV RNA load; U ¼ undetectable (<4000 copies/ml), L, low (4000-20 000 copies/ ml), M, moderate (20 001-100 000 copies/ml), and H, high (>100 000 copies/ml). Effect size was measured in odds ratios in Phelan et al. [28] and hazard ratios in Xie et al., 2013 and Strickler et al. [5] . Effect estimates from Mbulawa et al. [26] , Denny et al. [23] , and Mane et al. [25] were not included in the figure. Mbulawa et al. [26] used a different CD4 þ cell count cutoff (>350 vs. <350) and Denny et al. [23] and Mane et al. [25] evaluated CD4 þ cell count as a continuous variable. women with higher CD4 þ cell count (Fig. 3c) or HIVnegative women [26, 32, 34, 35, 37] . However, two studies found no difference in HPV clearance by CD4 þ cell count (Appendix Table 5 , http://links.lww.com/QAD/ B224) [25, 26] . In one study, clearance rates did not differ by HIV viral load (RR 0.77, 95% CI 0.51-1.16) but another found that every one log increase in viral load resulted in a 23% reduction in likelihood of clearance (hazard ratio 0.77, 95% CI 0.64-0.91) [26, 27] . ART did not impact clearance of any HPV infection, regardless of adherence or effectiveness (Appendix Table 5 , http:// links.lww.com/QAD/B224) [25, 27, 33] . However, one study found clearance of high-risk HPV infection other than HPV 16 or 18 was higher among women on ART compared with those not on ART (hazard ratio 2.20, 95% CI 1.22-3.98) [33] .
Progression to low-grade squamous intraepithelial lesions
Eight studies evaluated progression to LSIL from normal cytology [17, [37] [38] [39] [40] [41] [42] [43] and one study evaluated progression to LSIL from normal cytoloy or atypical squamous cells of undetermined significance (ASCUS) [23] . Among women with normal cytology at baseline, HIV-positive women had 3.73 times higher risk of progression to ASCUS or LSIL compared with HIV-negative women (95% CI 2.62-5.32; Fig. 4a ) [38] [39] [40] 44] . Among HIV-positive women, LSIL incidence in those with persistent HPV infection (detected at 2 visits 3-12 months apart) was 11 times higher with HPV 16 and 18 (95% CI 1.4-88.7) and 8.9 times higher with non-HPV 16 and 18 types (95% CI 1.2-66.2), compared with women without persistent HPV [39] . In one study, CD4
þ cell count and ART were no longer associated with LSIL incidence after adjusting for persistent HPV infection (Appendix Table 6 , http:// links.lww.com/QAD/B224) [39] .
LSIL risk was more than 30% lower in women on ART (hazard ratio pooled 0.65, 95% CI 0.52-0.82 and RR pooled 0.67, 95% CI 0.45-1.00; Fig. 4b [17, 39, [42] [43] [44] ). Risk of LSIL decreased with CD4 þ cell count gains after ART initiation (Fig. 4c) [44] . Controlling for CD4 þ cell count, women on ART had 34% lower risk of LSIL incidence compared with those not on ART (RR 0.66, 95% CI 0.47-0.92) [44] .
Progression to high-grade squamous intraepithelial lesions
Ten studies assessed progression to HSIL [4, 17, 34, 40, [45] [46] [47] [48] [49] [50] , seven compared progression by HIV status [34, 40, [45] [46] [47] [48] 50] . HIV-positive women had higher risk of developing HSIL compared with HIV-negative women (hazard ratio pooled 1.32, 95% CI 1.10-1.58; Appendix Figure 3 , http://links.lww.com/QAD/B224) [34, [45] [46] [47] . Two studies found persistence of HPV and LSIL were stronger predictors of progressing to HSIL than HIV status alone [45, 50] . Risk of progression to HSIL from HPV infection with normal cytology was three times higher among HIV-positive compared with HIV-negative women [34, 45] ; risk of progression from LSIL to HSIL was not significantly different by HIV status [40, 46, 47, 50] .
Two studies in HIV-positive women with LSIL or normal cytology did not find an association between ART and HSIL incidence (OR pooled 0.88, 95% CI 0.69-1.12) (Appendix Figure 3 , http://links.lww.com/QAD/B224) [4, 17] . However, the risk of progression to HSIL was 34% lower among women initiating ART before LSIL diagnosis and 36% lower among women on ART for at least 2 years [4, 47] . Risk of progression was higher in women with lower CD4
þ cell count at HSIL diagnosis regardless of ART use [17] . CD4 þ cell count, HIV status, and viral load were not associated with HSIL incidence after adjusting for persistent HR HPV infection (Appendix Table 6 , http://links.lww.com/QAD/B224) [46, 49] .
Low-grade squamous intraepithelial lesion regression
Eight studies evaluated LSIL regression [17, 41, 47, 48, [51] [52] [53] [54] ; three compared regression by HIV status [47, 48, 51] . The likelihood of regression was 33% lower among HIVpositive women (hazard ratio pooled 0.67, 95% CI 0.56-0.82; Fig. 5a ) and varied by age, CD4 þ cell count, ART, and treatment of lesions [47, 51] . One study found that for women not on ART, lower CD4 þ cell count was associated with reduced LSIL regression (Fig. 5b) [45] . Likelihood of regression from LSIL was 2.29 times higher among women receiving ART compared with those not on treatment (95% CI 1.56-3.37; Fig. 5c ) [17, 53] . Longer duration of ARTuse was associated with increased LSIL regression [47] .
High-grade squamous intraepithelial lesion regression One study evaluating HSIL regression in 173 HIVpositive and negative women with HSIL in Senegal found that HIV-positive women were 43% less likely to regress from HSIL to normal cytology (hazard ratio 0.57, 95% CI 0.26-1.29) and equally as likely to regress from HSIL to HPV infection (hazard ratio 1.06, 95% CI 0.71-1.59) [34] . Among HIV-positive women, likelihood of HSIL regression was 65% lower in women with HPV 16 and 18 compared with women infected with other types (hazard ratio 0.35, 95% CI 0.23-0.54) [34] .
Progression to cervical cancer Cervical cancer incidence was assessed in two studies [4, 55] . In the United States, the age-standardized cervical cancer incidence among HIV-positive women from cohorts in North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) was 4.1 times (95% CI 2.3-6.6) higher than expected in Surveillance, Epidemiology, and End Results registry for the general population [55] . A case-control study nested in NA-ACCORD, which compared HIV-positive women to HIV-negative women, found that relative risk of cervical cancer increased with decreasing CD4 þ cell count (Appendix Figure 4 , http:// links.lww.com/QAD/B224) [55] . Further, among HIVpositive women on ART, CD4 þ cell reconstitution halted in cervical cancer cases 3 years after initiating ART and 60 months before cervical cancer diagnosis, although matched controls (women who never developed cervical cancer) continued to gain CD4 þ cells [55] . A nested case-control study of the Swiss HIV Cohort Study found that ARTwas not associated with lower cervical cancer incidence, regardless of duration (Appendix Table 9 , http://links. lww.com/QAD/B224) [4] .
Discussion
HIV infection was associated with higher incidence of and reduced clearance of HPV infection. Women with low CD4 þ cell count and high HIV viral load had , and Ellerbrock et al. [39] adjusted for CD4 þ cell count. (c) LSIL incidence by absolute increase in CD4 þ cell count after ART initiation. Data extracted from [44] . ART, antiretroviral therapy; LSIL, low-grade squamous intraepithelial lesion. elevated risk of HPV acquisition, but risk was reduced among ART-adherent women. Low CD4 þ cell count was also associated with decreased HPV clearance. Although ART reduced LSIL incidence, its impact on HSIL incidence depended on the duration of use. HIV-positive women have lower likelihood of LSIL regression, and ART and high CD4 þ cell count were associated with increased LSIL regression. In contrast, HSIL regression was not associated with HIV status. However, the study that examined HSIL regression had a small sample size and should be interpreted with caution.
Although the relative risk of acquiring HPV 16 and 18 was higher among HIV-positive women, HPV 16 and 18 clearance was not found to differ by HIV status. This may be because of a lack of power or it may be that HPV 16 and 18 are better at evading the host immune system and are less impacted by HIV-associated immunosuppression [56, 57] . Studies have found that HPV 16 in particular is more weakly associated with the immune system compared with other types [58, 59] . This is consistent with studies that find HIV-positive women have a greater diversity of HPV types in normal cytology and low-grade lesions, but the relative prevalence of HPV 16 and 18 increases with severity of lesions and cervical cancer and the proportion of cervical cancer attributable to HPV 16 and 18 is similar between HIV positive and negative women [57, 60] . þ cell count. Data extracted from [48] . Confidence intervals for these estimates were not included in the study. (c) LSIL regression among HIV-positive women on ART compared with HIV-positive women not on ART. Data from Ahdieh-Grant et al. [52] was not included in the figure. As LSIL regression was not observed in any of the HIV-positive women not on ART, the study could not obtain an estimate for the effect of ART use on LSIL regression. ART, antiretroviral therapy; LSIL, low-grade squamous intraepithelial lesion.
HIV was also associated with higher LSIL and HSIL incidence, although the relative impact on HSIL was smaller. This suggests that immunosuppression related to HIV infection may play a greater role earlier in the course of HPV natural history, namely acquisition, persistence, and progression to low-grade lesions, whereas later stage carcinogenicity may be less dependent on immune function. This is consistent with cohort studies, which find that, although HIV-positive women have a high burden of abnormal cytology, the vast majority of lesions are low-grade, with only a small increased prevalence in HSIL [45, 61] . Therefore, HIV-positive women may be at risk for overtreatment in screening programs as they have a high prevalence of low-grade lesions that infrequently progress to HSIL. The United States has recently changed cervical cancer screening guidelines in HIV-positive women from annual screening to every 3 years after three consecutive normal screens [15] .
CD4
þ cell count in HIV-positive women is inversely associated with risk of HPV infection and cervical lesion progression. Further, several studies showed that women with high CD4 þ count (>500 cells/ml) had similar risk of HPV disease progression as HIV-negative women. Similar associations between immunosuppression and HPV risk have been observed in HIV-negative populations with impaired immune system [62] [63] [64] [65] . A metaanalysis of cancer incidence in HIV-positive persons and transplant recipients found both groups were at higher risk of cancers with infectious cause compared with the general population [65] . The destruction of CD4 þ cells by HIV may increase the likelihood of HPV establishing infection [66] . Recent evidence also suggests that immunosuppression leads to higher probability of HPV reactivation, potentially because of incomplete clearance of HPV DNA [67] .
HPV persistence likely plays an important role in the interactions between HIV and HPV. HIV-positive women with persistent HPV infection have dramatically higher incidence of precancerous lesions compared with those infected with HPV for less than 6 months [36, 39, 46] . Studies find after controlling for HPV persistence, CD4
þ cell count and ART use are no longer associated with increased risk of HPV disease progression. This is likely because HIVacts through HPV persistence to increase risk of precancerous lesions. Women infected with HPV for longer have a greater chance of developing cellular changes that lead to precancer or cancer.
The effect of ARTon HPV-related disease is less clear. An equal number of studies find ART is associated with reduced HPV disease progression and find no association between ART and HPV pathogenesis. The equivocal results may be because of changes in ART regimens over time or varying durations of ART use. The majority of studies showing no effect of ART used cohorts formed in the early days of ART. Because of high toxicity of the older ART drugs, healthier HIV-infected individuals likely delayed treatment initiation and had poor adherence. Therefore, the women who were on ART likely already had more advanced HIV disease at treatment initiation. Studies show that HIV disease state at ART initiation significantly impacts morbidity and mortality [68] [69] [70] . Further, many studies finding no association approximated ART use with medical records or selfreport. Studies using more accurate measures of ART adherence (e.g. viral suppression), found ART reduces HPV disease progression. One study found significantly lower incidence of HPV infection and cervical lesions in women who were virologically suppressed on ART compared with women who were not on ART or not virologically suppressed [27] . A study showed cervical cancer cases had higher odds of CD4 þ cell decline on ART prior to cervical cancer diagnosis compared with controls who did not subsequently develop cervical cancer, which may indicate a disruption in ARTuse prior to the development of cervical cancer [71] . A longer duration on ART is also associated with reduced HSIL incidence [4, 47] , which may indicate immune system recovery [72] .
In addition to the limitations of including studies that ascertained ART status through self-reports and chart reviews, another potential limitation of this review is the heterogeneity of studies included. Although majority of studies were longitudinal, variation in analysis, effect measures, and exposures definition limited our ability to perform quantitative analysis. Additionally, because of small number of studies eligible for some objectives, we could not use I 2 to quantify heterogeneity in many cases. High loss to follow-up was an issue for some of the studies we included. Although this limitation was ameliorated with survival analysis methods that censored individuals lost to follow-up, effect estimates may be biased in studies that did not address this limitation in their analysis. The magnitude and direction of bias would depend on whether the lost to follow-up was differential by HIV, ART, CD4 þ cell count, or viral load status.
This review identified gaps in the research on HPV and cervical precancer among HIV-positive women. There is a lack of studies investigating impact of ART on HPV disease progression using objective measures of adherence (e.g. viral suppression). Due to influence of HIV-related disease severity, evaluating HPV progression in by nadir CD4 þ cell count would be useful. Further, studies comparing HPV progression between HIV-positive women on ART with HIV-negative women can provide insight into cervical cancer risk of virally suppressed HIVpositive women. Finally, accurate estimates of cervical cancer incidence by HIV status are needed; national cancer registries do not currently document HIV status of cervical cancer cases.
